Ohid Yaqub: Gilead Sciences and American Patient

ohid yaqub: The Department of Health and Human Services said it had secured 500,000 treatments of the drug through September, representing 100% of Gilead's July production capacity and 90% of its capacity in August and September, according to CTV. To the extent possible, we want to ensure that any American patient who needs remdesivir can get it, Health and Human Services Secretary Alex Azar said in a statement. The U.S. government announced Monday that it had an agreement with Gilead Sciences to make the bulk of their production of remdesivir available to Americans during the next three months. Ohid Yaqub, a senior lecturer at the University of Sussex, called the U.S. agreement disappointing news. That ended Tuesday and Gilead this week announced the price of the treatment going forward. Newsletter sign-up Get The COVID-19 Brief sent to your inbox It so clearly signals an unwillingness to co-operate with other countries and the chilling effect this has on international agreements about intellectual property rights, Yaqub said in a statement Until now, Gilead had donated treatment courses to the U.S. and other countries. (www.immigrantscanada.com). As reported in the news.